PL3448416T3 - Semaglutyd w schorzeniach sercowo-naczyniowych - Google Patents

Semaglutyd w schorzeniach sercowo-naczyniowych

Info

Publication number
PL3448416T3
PL3448416T3 PL17721109.1T PL17721109T PL3448416T3 PL 3448416 T3 PL3448416 T3 PL 3448416T3 PL 17721109 T PL17721109 T PL 17721109T PL 3448416 T3 PL3448416 T3 PL 3448416T3
Authority
PL
Poland
Prior art keywords
semaglutide
cardiovascular conditions
cardiovascular
conditions
Prior art date
Application number
PL17721109.1T
Other languages
English (en)
Polish (pl)
Inventor
Oluf Kristian Højbjerg HANSEN
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58668875&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3448416(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of PL3448416T3 publication Critical patent/PL3448416T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
PL17721109.1T 2016-04-28 2017-04-28 Semaglutyd w schorzeniach sercowo-naczyniowych PL3448416T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16167458 2016-04-28
EP16188262 2016-09-12
PCT/EP2017/060160 WO2017186896A1 (en) 2016-04-28 2017-04-28 Semaglutide in cardiovascular conditions

Publications (1)

Publication Number Publication Date
PL3448416T3 true PL3448416T3 (pl) 2022-11-07

Family

ID=58668875

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17721109.1T PL3448416T3 (pl) 2016-04-28 2017-04-28 Semaglutyd w schorzeniach sercowo-naczyniowych

Country Status (24)

Country Link
US (3) US20190134162A1 (enExample)
EP (1) EP3448416B1 (enExample)
JP (1) JP7221694B2 (enExample)
KR (3) KR102778218B1 (enExample)
CN (1) CN109069589B (enExample)
AU (2) AU2017256774B2 (enExample)
BR (1) BR112018072020A2 (enExample)
CA (1) CA3022535A1 (enExample)
CL (1) CL2018003045A1 (enExample)
DK (1) DK3448416T3 (enExample)
ES (1) ES2928007T3 (enExample)
HR (1) HRP20221150T1 (enExample)
HU (1) HUE060040T2 (enExample)
IL (1) IL262390B1 (enExample)
MA (1) MA44762A (enExample)
MX (1) MX2018012700A (enExample)
MY (1) MY202967A (enExample)
PH (1) PH12018502274B1 (enExample)
PL (1) PL3448416T3 (enExample)
RS (1) RS63630B1 (enExample)
RU (1) RU2768283C2 (enExample)
SI (1) SI3448416T1 (enExample)
WO (1) WO2017186896A1 (enExample)
ZA (2) ZA202507394B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018012700A (es) * 2016-04-28 2019-01-30 Novo Nordisk As Semaglutida en afecciones cardiovasculares.
EP3474820B1 (en) 2017-08-24 2024-02-07 Novo Nordisk A/S Glp-1 compositions and uses thereof
JP7422754B2 (ja) * 2018-10-26 2024-01-26 ノヴォ ノルディスク アー/エス 安定性セマグルチド組成物およびその使用
WO2020127950A1 (en) * 2018-12-21 2020-06-25 Novo Nordisk A/S Process of spray drying of glp-1 peptide
PE20230819A1 (es) * 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1
CN114699510B (zh) * 2021-12-29 2024-07-16 浙江湃肽生物有限公司 一种司美格鲁肽微针阵列及其制备方法
WO2023238017A1 (en) * 2022-06-08 2023-12-14 Zydus Lifesciences Limited Reusable multi-dose, variable dose, single pen injector for type 2 diabetes and weight management
CN117462654A (zh) * 2023-09-28 2024-01-30 武汉大学人民医院(湖北省人民医院) 司美格鲁肽在制备预防或治疗心肌重构的药物中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005535569A (ja) * 2002-04-04 2005-11-24 ノボ・ノルデイスク・エー/エス Glp−1アゴニスト及び心臓血管合併症
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
CA2797310C (en) * 2010-05-05 2020-03-31 Boehringer Ingelheim International Gmbh Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
RU2600440C3 (ru) 2010-12-16 2021-12-10 Ново Нордиск А/С Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
US20130035281A1 (en) 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
ES2626013T3 (es) * 2011-09-06 2017-07-21 Novo Nordisk A/S Derivados de GLP-1
US9085637B2 (en) * 2013-11-15 2015-07-21 Novo Nordisk A/S Selective PYY compounds and uses thereof
MX2018012700A (es) * 2016-04-28 2019-01-30 Novo Nordisk As Semaglutida en afecciones cardiovasculares.

Also Published As

Publication number Publication date
RU2018140900A3 (enExample) 2020-09-28
CA3022535A1 (en) 2017-11-02
KR102778218B1 (ko) 2025-03-10
HUE060040T2 (hu) 2023-01-28
US20190134162A1 (en) 2019-05-09
IL262390B1 (en) 2023-05-01
JP2019514925A (ja) 2019-06-06
AU2017256774A1 (en) 2018-11-01
WO2017186896A1 (en) 2017-11-02
MY202967A (en) 2024-05-31
ZA202507395B (en) 2025-09-25
EP3448416A1 (en) 2019-03-06
CN109069589A (zh) 2018-12-21
BR112018072020A2 (pt) 2019-02-12
SI3448416T1 (sl) 2022-10-28
CL2018003045A1 (es) 2018-12-14
KR20250038818A (ko) 2025-03-19
HRP20221150T1 (hr) 2022-11-25
AU2017256774B2 (en) 2024-07-11
AU2024227113A1 (en) 2024-10-31
MA44762A (fr) 2019-03-06
DK3448416T3 (da) 2022-10-03
MX2018012700A (es) 2019-01-30
ES2928007T3 (es) 2022-11-14
RS63630B1 (sr) 2022-10-31
EP3448416B1 (en) 2022-08-10
CN109069589B (zh) 2022-09-06
IL262390A (en) 2018-12-31
US20250288649A1 (en) 2025-09-18
JP7221694B2 (ja) 2023-02-14
PH12018502274A1 (en) 2019-09-09
KR20220147712A (ko) 2022-11-03
US20250262281A1 (en) 2025-08-21
RU2768283C2 (ru) 2022-03-23
ZA202507394B (en) 2025-09-25
KR20180135012A (ko) 2018-12-19
RU2018140900A (ru) 2020-05-28
PH12018502274B1 (en) 2024-02-28

Similar Documents

Publication Publication Date Title
GB201613024D0 (en) Compositions and methods
IL252216A0 (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
IL262390A (en) Semaglutide in cardiovascular conditions
TWI560818B (en) Electronic package and the manufacture thereof
IL297057B2 (en) Conjunctions and their uses
IL256020B (en) Igfbp3 and uses thereof
GB201512044D0 (en) Application in German
GB201521304D0 (en) Tokenisation in cardholder - not - present transactions
GB201521190D0 (en) Application in german
TWI561958B (en) Integrated circuit
IL254241A0 (en) Etv2 and its uses
GB201603976D0 (en) Application in foreign
ZA201805538B (en) Liraglutide in cardiovascular conditions
GB201407256D0 (en) Sercure token implementation
GB201523035D0 (en) In terferometry
GB201505011D0 (en) Improvements in packages
GB201512996D0 (en) Compositions and methods
GB201521191D0 (en) Application in german
GB201603974D0 (en) Application in foreign
PT3448416T (pt) Semaglutido em condições cardiovasculares
GB201508643D0 (en) Improvements in shirts
GB201514413D0 (en) Compositions and methods
PT3423082T (pt) Liraglutida em condições cardiovasculares
GB201618109D0 (en) Improvements in drawing boards
GB201522554D0 (en) Methods and compositions